Johnson & Johnson Overvalued by 101% According to DCF Analysis

Johnson & Johnson (JNJ) has seen a substantial 40.8% increase in its stock price over the past year, but recent analysis suggests the company may be significantly overvalued. A discounted cash flow (DCF) analysis conducted on October 5, 2026, estimates JNJ's intrinsic value based on earnings at $126.87, far below its current price of $256.03. This results in a negative margin of safety of -101.8%, indicating that the stock is overvalued.

The DCF analysis uses a two-stage model, projecting an 8.5% annual growth rate in earnings per share (EPS) for the next ten years, followed by a terminal growth rate of 4%. The discount rate applied is 12%, derived from the risk-free rate and equity risk premium. Even when considering free cash flow (FCF), the intrinsic value is estimated at $97.73, reinforcing the conclusion that JNJ is overvalued.

The GF Value™, a proprietary measure by GuruFocus, also supports this assessment, valuing JNJ at $194.07. Despite JNJ's strong fundamentals, reflected in a GF Score™ of 83/100, the stock's low predictability rank of 0/5 stars suggests that DCF models may be less reliable for this company. Additionally, insider activity shows net selling over the past 12 months, which may signal caution among company insiders.

While 24 investment gurus currently hold JNJ, with 5 adding and 14 trimming their positions, the consensus from all three valuation models, DCF earnings, DCF FCF, and GF Value™, is that JNJ is overvalued at its current price. Investors should consider these findings carefully before making any decisions.